Humacyte is trading 8.82% down at $0.67 in pre-market, with no new company-specific announcement, filing, earnings release, or analyst action found to explain the decline.
- The stock is reversing part of its 26.34% gain to $0.73 recorded on August 19.
- The latest major news was positive Phase 3 dialysis-access data published in The Lancet Digital Health on August 19.
- That report supported the prior session’s rally rather than explaining the August 20 decline.